

**Freedom of Information Act 2000****The Royal Cornwall Hospitals NHS Trust Response to Information request****Date Request Received: 10 6 2024****FOI Ref No: 24999****Requested Information**

Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
- Amivantamab
- Atezolizumab Monotherapy
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
- Dabrafenib + Trametinib
- Docetaxel monotherapy or in combination with Carboplatin/Cisplatin
- Durvalumab
- Gemcitabine
- Nitedanib + Docetaxel
- Nivolumab
- Osimertinib
- Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
- Paclitaxel
- Pembrolizumab Monotherapy
- Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
- Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)
- Pemetrexed + Platinum (Carboplatin/Cisplatin)
- RET Inhibitors (Pralsetinib, Selpercatinib)
- Sotorasib
- Tepotinib
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
- Other active systemic anti-cancer therapy
- Palliative care only

**Response**

Q1. Royal Cornwall Hospitals Trust treated the following numbers of patients (excluding clinical trials) for Non-small cell lung cancer (NSCLC) between February and April 2024 with:

- ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) **9**
- Amivantamab **0**
- Atezolizumab Monotherapy **4**
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel **0**
- Dabrafenib + Trametinib **0**
- Docetaxel monotherapy or in combination with Carboplatin/Cisplatin **0**
- Durvalumab **2**
- Gemcitabine **1** (plus 3 patients also administered Nivolumab included below)
- Nintedanib + Docetaxel **1**
- Nivolumab **10** (including 3 patients also administered Gemcitabine + carboplatin and 3 Pemetrexed + carboplatin)
- Osimertinib **20**
- Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) **2**
- Paclitaxel **4**
- Pembrolizumab Monotherapy **57**
- Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) **5**
- Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) **11**
- Pemetrexed + Platinum (Carboplatin/Cisplatin) **0**
- RET Inhibitors (Pralsetinib, Selpercatinib) **0**
- Sotorasib **4**
- Tepotinib **1**
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin **2**
- Other active systemic anti-cancer therapy:
  - Denosumab **11**
- Palliative care only – This information is not recorded and would exceed the ‘appropriate limit’ under section 12 of the Freedom Of Information Act.

**Attachment(s)****Date Response sent:**